Effects of olaparib on Metastatic Castration-Resistant Prostate Cancer

Olaparib provides considerably longer imaging-based progression-free survival than the enzalutamide or abiraterone when received by men who have metastatic castration-resistant prostate cancer who undergo BRCA1, BRCA2, or ATM mutations and who experienced disease progression while getting a new hormonal agent.

In a randomized study, olaparib was evaluated in men suffering from metastatic castration-resistant prostate cancer who had disease progression during the treatment with a new hormonal agent. In group A there were 245 patients who had a minimum of one modification in BRCA1, BRCA2, or ATM, and in group B there were 142 patients who had alterations in any of 12 other prespecified genes. The patients were randomly allotted in the ratio of 2:1 to get olaparib or enzalutamide or abiraterone (control). Imaging-based progression-free survival was the primary endpoint in group A.

In group A, the imaging-based progression-free survival was considerably extended in the olaparib arm compared to the control arm. Considerable assistance was also seen regarding the confirmed time to pain progression and objective response rate. In group A, the median overall survival was 18.5 months in the olaparib arm. While in the control arm, the median overall survival was 15.1 months. 81% of the patients from the control arm who had progression moved to receive olaparib.

A considerable olaparib benefit was observed in both groups A and B for imaging-based progression-free survival.

Nausea and anaemia nausea were the significant toxic effects observed in patients who administered olaparib.

It was concluded that in men who have metastatic castration-resistant prostate cancer who experienced disease progression while receiving enzalutamide or abiraterone and who had gene modification, olaparib was linked with more prolonged progression-free survival and better patient-reported endpoints and measures of response in comparison to enzalutamide or abiraterone.